Buprenorphine and naloxone is a combination medication used to treat opioid addiction in adults. Sold under the brand name Suboxone and several generics, it works by reducing cravings and withdrawal symptoms so people can stabilize their lives while recovering from dependence on opioids like heroin, fentanyl, or prescription painkillers. It is not a standalone cure. The FDA approves it only as part of a complete treatment plan that includes counseling and behavioral therapy.
How the Two Ingredients Work Together
Each ingredient in the combination serves a distinct purpose. Buprenorphine is the active treatment component. It’s a partial opioid agonist, meaning it activates the same brain receptors that heroin or oxycodone would, but only partially. Think of it like a key that fits the lock but only turns halfway. That partial activation is enough to ease withdrawal symptoms and quiet cravings, but it produces a much weaker effect than a full opioid. This “ceiling effect” means that taking more of it beyond a certain dose doesn’t increase the high, which makes it considerably safer than full opioids.
Buprenorphine also binds very tightly to opioid receptors and is slow to let go. This matters because while it’s occupying those receptors, other opioids can’t fully activate them. If someone uses heroin or fentanyl while on buprenorphine, the effect is blunted. That tight binding also contributes to a lower risk of physical dependence compared to full opioids like methadone.
Naloxone is the second ingredient, and its role is entirely about discouraging misuse. When you take the medication as directed (dissolved under the tongue), naloxone is barely absorbed into the bloodstream, less than 10% bioavailability. It essentially does nothing. But if someone crushes the film or tablet and injects it, naloxone enters the bloodstream in full force. As a pure opioid blocker, it immediately knocks other opioids off the brain’s receptors and triggers rapid, uncomfortable withdrawal. This built-in deterrent is the reason naloxone is included in the formulation.
Who This Medication Is For
The combination is prescribed to adults who are physically dependent on opioids, whether from prescription painkillers, heroin, or synthetic opioids like fentanyl. It is classified as a Schedule III controlled substance, meaning it has accepted medical use but still carries some potential for misuse. For years, doctors needed a special federal waiver to prescribe it, with caps on how many patients they could treat. Those restrictions have been loosened over time to expand access during the opioid crisis.
Buprenorphine/naloxone is not typically the first thing given during the very earliest stage of treatment. Patients usually begin with buprenorphine alone during the initial “induction” phase, then transition to the combination product for ongoing maintenance.
Starting Treatment: The Induction Process
One of the most important things to understand about this medication is that you cannot start it while opioids are still active in your system. Because buprenorphine binds so strongly to opioid receptors, it can displace whatever opioid is already there without fully replacing its effect. The result is called precipitated withdrawal: a sudden, intense onset of withdrawal symptoms that feels far worse than letting withdrawal happen naturally.
To avoid this, you need to already be in mild to moderate withdrawal before taking the first dose. The timing depends on which opioid you’ve been using. For short-acting opioids like heroin or immediate-release oxycodone, that typically means waiting 6 to 12 hours after your last use. For long-acting formulations of morphine or oxycodone, the wait is at least 24 hours. For methadone, which leaves the body very slowly, the wait is at least 72 hours. Your prescriber will use a standardized scale to assess whether you’re far enough into withdrawal to begin safely.
What Maintenance Treatment Looks Like
Once you’re stabilized, the medication is taken once daily. It comes as a sublingual film or tablet that dissolves under the tongue or against the inside of the cheek. The recommended target dose is 16 mg of buprenorphine with 4 mg of naloxone, though the actual maintenance range varies from 4/1 mg to 24/6 mg per day depending on individual needs. Finding the right dose is a process you work through with your prescriber over the first several days to weeks.
During the early adjustment period, the medication can affect alertness and coordination. Driving and operating machinery may be impaired until your body adjusts to a stable dose. Most people notice this effect easing as they settle into their maintenance regimen.
Common side effects include headache, nausea, sweating, constipation, and insomnia. These tend to be most noticeable during induction and often improve over time. Because buprenorphine is still an opioid, combining it with alcohol, benzodiazepines, or other sedatives increases the risk of dangerous respiratory depression.
How Effective Is It?
Buprenorphine-based treatment significantly reduces illicit opioid use and overdose deaths compared to no medication at all. However, staying on treatment long-term remains a challenge. A large review of 569 patients started on buprenorphine between 2020 and 2022 found that by the following year, only about 20% were still actively or recently engaged in treatment, while 80% had disengaged. This doesn’t mean the medication failed for all of those people. Some may have transitioned to other treatments, completed a planned taper, or re-engaged later. But it highlights why ongoing counseling and support systems are considered essential parts of the treatment plan.
How does it compare to methadone, the other major medication for opioid addiction? A large study published in JAMA found that the risk of dying while on treatment was similar between buprenorphine/naloxone and methadone, with mortality rates below 0.15% at 24 months for both. The biggest practical differences are in how the two medications are accessed. Methadone for addiction treatment must be dispensed at a licensed clinic, often requiring daily visits. Buprenorphine can be prescribed in a regular doctor’s office and picked up at a pharmacy, giving patients far more flexibility in their daily lives.
Why It’s Not Just About the Medication
Buprenorphine/naloxone addresses the physical side of opioid dependence: the cravings, the withdrawal, and the neurological pull to keep using. What it doesn’t address on its own is the behavioral, emotional, and social drivers of addiction. This is why every clinical guideline emphasizes using it alongside counseling, whether that’s cognitive behavioral therapy, group support, contingency management, or other psychosocial approaches. The medication creates a stable foundation. The therapy helps rebuild what addiction disrupted.